We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
H&R Block's (HRB) Q4 Earnings, Revenues to be Hit by Coronavirus
Read MoreHide Full Article
H&R Block, Inc. (HRB - Free Report) is scheduled to report fourth-quarter fiscal 2020 results on Jun 16, after the bell.
Shares of the company have declined 18.6% year to date, compared with the 4.8% decline of the industry it belongs to.
Q4 Results to Reflect Impacts of the Pandemic
H&R Block’s financial performance in the to-be-reported quarter is expected to have been significantly impacted by a delayed tax season in response to the coronavirus pandemic. The deadline for Federal filing has been extended to Jul 15. Moreover, as small businesses have been badly hit by the pandemic, volumes through the company’s Wave payments platform are likely to be low.
Notably, the Zacks Consensus Estimate for revenues in the to-be-reported quarter is pegged at $1.73 billion, indicating year-over-year decline of 25.6%. In third-quarter fiscal 2020, revenues of $519.2 million increased 10.9% year over year.
The consensus estimate for H&R Block’s earnings is pegged at $3.01, indicating year-over-year decline of 30.3%. In third-quarter fiscal 2020, the company incurred loss of 59 cents per share that increased 1.7% year over year.
Recent Performance of Some Other Business Services Companies
S&P Global Inc.’s (SPGI - Free Report) first-quarter 2020 adjusted earnings per share of $2.73 beat the consensus mark by 15.7% and improved 29.4% year over year on the back of revenue growth, benefits of productivity initiatives and reduced business travel. The stock currently carries a Zacks Rank #3 (Hold).
IQVIA Holdings Inc.’s (IQV - Free Report) first-quarter 2020 adjusted earnings per share of $1.50 beat the consensus mark by 1.4% but decreased 1.9% on a year-over-year basis. The reported figure lies within the guided range of $1.46-$1.51. The stock currently carries a Zacks Rank #3.
Insperity, Inc.’s (NSP - Free Report) first-quarter 2020 adjusted earnings of $1.70 per share beat the consensus mark by 5.6% but decreased 14.1% year over year. The reported figure matched the higher end of the guided range of $1.61-$1.70. The stock currently carries a Zacks Rank #4 (Sell).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released “Century of Biology: 7 Biotech Stocks to Buy Right Now” to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
H&R Block's (HRB) Q4 Earnings, Revenues to be Hit by Coronavirus
H&R Block, Inc. (HRB - Free Report) is scheduled to report fourth-quarter fiscal 2020 results on Jun 16, after the bell.
Shares of the company have declined 18.6% year to date, compared with the 4.8% decline of the industry it belongs to.
Q4 Results to Reflect Impacts of the Pandemic
H&R Block’s financial performance in the to-be-reported quarter is expected to have been significantly impacted by a delayed tax season in response to the coronavirus pandemic. The deadline for Federal filing has been extended to Jul 15. Moreover, as small businesses have been badly hit by the pandemic, volumes through the company’s Wave payments platform are likely to be low.
Notably, the Zacks Consensus Estimate for revenues in the to-be-reported quarter is pegged at $1.73 billion, indicating year-over-year decline of 25.6%. In third-quarter fiscal 2020, revenues of $519.2 million increased 10.9% year over year.
The consensus estimate for H&R Block’s earnings is pegged at $3.01, indicating year-over-year decline of 30.3%. In third-quarter fiscal 2020, the company incurred loss of 59 cents per share that increased 1.7% year over year.
H&R Block currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Recent Performance of Some Other Business Services Companies
S&P Global Inc.’s (SPGI - Free Report) first-quarter 2020 adjusted earnings per share of $2.73 beat the consensus mark by 15.7% and improved 29.4% year over year on the back of revenue growth, benefits of productivity initiatives and reduced business travel. The stock currently carries a Zacks Rank #3 (Hold).
IQVIA Holdings Inc.’s (IQV - Free Report) first-quarter 2020 adjusted earnings per share of $1.50 beat the consensus mark by 1.4% but decreased 1.9% on a year-over-year basis. The reported figure lies within the guided range of $1.46-$1.51. The stock currently carries a Zacks Rank #3.
Insperity, Inc.’s (NSP - Free Report) first-quarter 2020 adjusted earnings of $1.70 per share beat the consensus mark by 5.6% but decreased 14.1% year over year. The reported figure matched the higher end of the guided range of $1.61-$1.70. The stock currently carries a Zacks Rank #4 (Sell).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released “Century of Biology: 7 Biotech Stocks to Buy Right Now” to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>